YouTube Deep Summary

Hey, I'm Kramer. Welcome to Mad Money. Welcome to Kramer. I'll do my friends. I'm just trying to make you a little extra money. My job is not just to entertain, but to educate, to teach you. So call me at 1800 743 CBC. Tweet me at Jim Kramer. You always wish you had a stock that went up 10 bucks in a day. And today we had a bunch of them. It's a sign that there is a gigantic change of foot, possibly the beginning of something that can make you a lot of money in a buoyant market where we get strong retail sales numbers allowing the Dow to gain 230 points. S&P advanced.54%. NASDAQ climbed.74%. It might be worth going over the anatomy of a 10-point gain in a large cap stock because I now think that there are many of these to be had. I want you to have one. We just need to figure out what we're looking for. First, the good news. These gains are anything but isolated. We're getting a bunch of them each day. Today, we sold PepsiCo sort about 10 bucks. PepsiCo. Why? Better than expected numbers, of course. a turn in the fortunes of unhealthy foods, better executions, and a look of a variety of different products. Pepsco isn't some tiny micro cap stock. It's not like some meme cyber player or uranium bottle rocket. And it is not part of the Palanteer Empire. They probably have something in your fridge or your pantry. Take that, Palanteer. We saw Eaton and Parker Hannifany. If you're from the Midwest, these are destination places. sore. But those are a function of strong data center orders that came from lead contractors ABB and Lrand to European construction companies that just reported that are huge builders of these warehouses full of servers. There's no doubt that the data center buildout is the single biggest construction boom per perhaps since World War II. You can see it if you look at Oracle every day by the way. I like the buildout. There are many many orders coming to them. I keep telling you these stocks are good. Parker and rose $13. Eaton jumped more than $17 or nearly 5% as investing club holders know that eaten move turned my earning season around because it's a core position my travel trust. Although a few minutes after I learned about the ecstasy of Eaton's victory, I had the agony of Abbott's defeat. So that's something we'll discuss momentarily because I'm a massochist and I don't want to pretend that everything I do is right cuz it isn't. Now sometimes in this game you do just get lucky. You'll come across a a a surprise quarter that tells you everything you need to know about what can cause a big cap stock to rally 10 points in a session. You'll see how a star is born and even get a blueprint for what you need, what you should be looking for. Yesterday, we got a beautiful schematic from none other than Johnson and Johnson. Boy, talk about something that's name brand in your house, which handed you a 10-point victory for the ages. Here's the the stock of a story company, one of just two AAA balance sheet companies with a solid dividend yield and great prospects. Everyone knows this company. Everyone I mean lately it stock has languished though because of litigation. The lawsuits alleging that their talc based products contain asbesus. J&J baby powder used to use talc though it's been phased out. The plaintist bar using what J&J calls junk science. I like that in the conference call has recruited more than 80,000 people who claim that that talc could contain asbesus and gave them cancer. It's kept the lid on the stock. I think that lid is about to I think that J&J is going to win this, but it's going to take a little while. In the meantime, though, the lid just blew off the stock yesterday. And it rallied more than 10 points. Least expected rally that I've seen in ages. But you know what? This company put on a clinic that showed you exactly how you can orchestrate such a big gain. So, why don't we why don't we just take part in the clinic? Well, like we'll attend it remotely. What does it take? Surprises. Many surprises. That's what and I'm going to go over them because it's terrific to have an earning scorecard/s schematic of what a winner looks like. If another company can do something similar, then I think 10 points of upside are just the beginning, including what's going to happen for J&J. Yes, I think that J&J's big move is just starting. So, what did J&J have going for it? First, point blank, you got the holy quadruple. That's J&J beating sales and earnings estimates for the quarter and then raising their sales and earnings guidance for the future. You got to have all four for a stock to go up. And they have to be dramatic. J&J raises fullear reported sales guidance by $2 billion to midpoint its earnings per share guidance by 25 cents. That's just a monster set of numbers for a company whose stock has been languishing. Second, in the case of the pharmaceutical industry, you need to show some breakthroughs. J&J revealed some results of a 5-year trial that showed how the their multiple myyoma immunotherapy is bringing a real life-saving hope to patients suffering from this horrendous form of cancer. Third, the company has to have good news on the tariff front. In this case, J&J had previously put out some very high estimates for the cost of tariffs, and they took them down dramatically. You know what? That made me feel triv because there are too many companies that are going to have to raise their tariff estimates, which will crush their stocks. For J&J, they cut their tariff forecast from $400 million down to 200 million. I'm calling that better than a sharp stick in the eye. Fourth, we know that there's some sense in the White House that other countries have been abusing us by manipulating their currencies lower, making their exports artificially cheaper versus stuff that we make. Now, the shoes on the other foot with the dollar coming down. The company estimates that it will have an incremental positive FX impact positive of $1.1 billion versus his previous guidance. That's outstanding. If you own mold and national stocks, you may be in for huge positive surprises. just like you know that you know it's like one of those things where like if you collect foul money that's been missing that's what this is collecting foul money that's been missing certainly worth looking for fifth you have to uh be able to offset what's going away and every business there are products that become less than important or are copycatted or leaprogged they become obsolete the drug business is a formal exclusivity process governed by the patent office when there's a loss of exclusivity l it creates a big hole J&J Stellera a big time immuno autoimmune New drug just lost exclusivity. At one point it generated more than $10 billion a year for this company. Yeah. And now it's just going no patent protection. Eviscerated blowing a huge hole in earnings. But you know what? J&J is such an outstanding company. It gave you a 15.5% operational growth for its farm business including 13 brands with double digit growth. In other words, amazingly Stella won't be missed. I never thought that could happen. I thought that this would be the stench of Stella six. If there was something wrong last quarter, it better be fixed. Well, J&J's medtech tech division truly disappointed last quarter. It was a major reason why the stock's doing poorly. VA Medtech was a bonafide allstar, something that very few thought possible. Seventh, you need big margin expansion always. This quarter didn't have good gross margins, something it was expected, but J&J did say it expects to see 300 basis points of operating margin expansion. Future margin improvement, margin improvement. Oh, we love that. Eighth, I love jaw-dropping projections. There were an incredible number of these on the conference call, including a stunning claim that by 2030, J&J will be the number one in oncology with sales of more than $50 billion. Talk about something that makes you want to take a long-term position. They also announced a bladder cancer breakthrough, which could be worth $5 billion in peak sales and would mean so so much for the patients. Holy cow, very tough cancer. J&J has something for it. Ninth, major healthc care companies buy other or companies for growth. That's just what they do. I'd been concerned that the companies J&J bought for its cardio franchise were overp payments, indicating that management doesn't know how to make acquisitions. This is something I'm very concerned about about Bristol Myers. By the way, just so you know, it turned out it was I was wrong in my judgment about J&J. The heart products we saw were remarkable. Let's hope that's the same for Bristol Myers and their neuro business. Finally, we want to know that the company has figured out that we want growth, high growth, and then more growth. And we don't want so-called safety. Uh safety is like Listerine, Neutrogena, Band-Aids, and Tylenol products that can be knocked off by anyone with Amazon just eviscerating them on price. J&J had the foresight to spin off the underperforming Ken View mix of consumer products that including those before they imploded, which we saw earlier this week. Some people second guess J&J. Not after this week. You do these 10 things right, or even just half of them, and I'm telling you, your stock's going to explode higher. If you didn't do it, if you failed to beat and raise or if you cut for heaven's sake like Abbott Labs did, a company we're gonna have on tonight, well, I say look out below. The bottom line, check your stocks. Do they have a chance to change their stripes like J&J? Do they fit the formula? Remember, J&J is just beginning its move. Then you know what? You may be just sitting on, say it with me, a gold mine. Joe in Massachusetts. Joe, hi Jim. My three-year-old son and I watch a show every night. He loves the buttons. I think the kids got horse sense. So, what's happening? My stock is down 11% from the all-time highs. Do I buy more now or wait for the tariff updates? My stock is Costco. No. Look, here's the problem with Costco. It is a victim of its own success. All it really does is ever go up and then has these periods where it languishes. We're in the languish period. That's when you buy Costco. Do I think Costco's in trouble? 50 times earnings. Are you kidding me? I think Costco's I still think Costco may be the one of the top five companies of all time. That is no sl to Jensen Wong because he's number one. Never do that. All right. With earning season in full swing, it's time to check your stocks to see if they can fit the formula I just gave you. Write that for. That checklist is actually pretty good. Took me all day. Now on man money tonight, Abid Labs just got slammed today after reporting earnings. Buying opportunity, cost of concern, heartache, cheap scotch, lolium floor. I'll find out. Then the callers of crime America stumped me on a little thing called Newax Health and then a bigger thing called Flex LG. So tonight I'm digging into both names to tell you where I come down. And the price of gold and copper have soared so far in 2025. But are the miners cash in on the rally? Hey, I've got the CEO of Barrack Mining. He had a read on the state of the commodity space and he'll tell us whether we can make up the copper that we everyone thinks we don't have in this country. So, I may I suggest that you stay with Kramer. Don't miss a second of MadMoney. Follow Jim Kramer on X. Have a question? Tweet Kramer #madmentions. Send Jim an email to madmoney@cnbc.com or give us a call at 1800743 CNNBC. Miss something, head to madmoney.cnbc.com today. an otherwise positive market. I was discouraged to get a mixed update from Abbott Labs, medical technology company that we've long owned for the charitable trust and I'd say two decades. When Avid Labs reported this morning the headlines results were perfectly solid, management tightened their fullear earnings guidance rather than raising it while also ticking down their organic sales growth forecast and their operating margin outlook. A lot of investors, including me, have been hoping they'd raise these numbers so the stock got clobbered down more than $11 or 8.5%. I thought it might been down $15. That's what I predicted. It didn't get that low. As I've chronicled many times, this is a stock where we've really had to battle over the past several quarters. We've kept our faith for the travel trust during some nasty litigation last year. The stock bounced back from that. But after today's guidance, I'm beginning to wonder if the juice is worth the squeeze. So, let's go directly to the source with Robert Fores, the chairman CEO of Abbott Labs to let him make the case for the stock comes on in good and bad times. I like that. Mr. Ford, welcome back to Man B M B M B M B M B M B M B M B M B M B Money. Well, thank you for having me, Jim. Okay, so Robert, we know that there were many good things that happened, but let's just touch on on what went wrong uh in diagnostics because while it was not the biggest division, it certainly had an incredible impact today and maybe you can put it in perspective to make people feel like that this is not the end of the world for Abbott Labs. Well, thank you, Jim. And first of all, it's very important for us that we've got our credibility and we deliver what we say we're going to deliver. And that's what we did in Q2. We delivered high singledigit sales growth. We delivered EPS growth of 11% ahead of the street gross margin expansion of 100 basis points like we had committed and a lot of pipeline activity. We even got our tariff to manageable numbers. So like to your point, we were really in a position to be able to kind of raise our guidance. What ended up happening is what we saw in the quarter was that the recovery that we had planned for our diagnostic business specifically in China we did not see the recovery the same way that we had projected for other places. So the United States grew 7%, Europe grew 8%, Latin America grew 16%. So we saw the recovery in our diagnostic business everywhere except China. So what we did today in our guidance was we said we're going to delay that recovery in China from Q2 to Q4 and that brought down uh the the uh the guidance of the revenue growth of specifically of that business. So what do you what are you left with after this guy Jim? We've got a $44.5 billion revenue business growing 7 12 to 8% doubledigit EPS a lot of margin expansion a very rich pipeline and ultimately really the fundamentals of our business are intact so I maintained our guidance for 2026 in terms of high singledigit growth and doubledigit EPS and a lot of the reports that are coming out right now they haven't changed their price targets and they haven't changed their forecast I think this is a little bit of an overreaction of Of course, we are all over this. We're focused on this, but the fundamentals of the entire rest of the company are pretty much intact and this is just really a point in time that we have to get. It's $20 billion valuation loss for one particular division and one real issue. But what I heard you say and what scared me today, and I use the word scare very rarely, is that it's a couple of quarters. This is not something that's going to be solved next quarter, which made me think, you know what, sell the stock, maybe a buy it back lower. Uh there's no hurry anymore to own Abbott Labs. Well, I want to make sure obviously we want the recovery to be as fast as possible and and we're all over this. We've made management changes. We've uh we spend every single week we meet with the diagnostic team. So, we're all over this, Jim. And if we can get it to recover in Q3, that'll be great. Uh but I think the prudent thing here was just to plan for that recovery more in Q4. Why did you think that? But the fundamental but remember in the last quarter in the last quarter you did make me feel like that this was not going to be a problem. I think that one of the problems was was that you believe this thing was coming to a conclusion in the same way unfortunately with co I mean the co test it was such a great thing you did but it just turns out to be something that just never ends as a problem now as opposed to a solution. Well I'm trying to I'm trying to end that problem Russell. We brought our CO forecast down also uh and and took that out of the of the second half. I realize that's a challenge. I mean, if you look at our revenue without CO, the forecast that the street had was 8 to 8 1/2. It's now 7 1/2 to 8. So, you had a 50 60 basis point drop in revenue growth and now I'm we were down 8% because of that. I I think that's a little bit of an overreaction. Well, I I can't disagree, but then again, it's the market, so I can't say market, you're wrong. I can't go home and tell my wife, you know, we did great in Abbott today. The market didn't say so what we did. Medical devices, meanwhile, has been incredibly strong. You had 12.2% organic growth. Tell us about that because that's the most important. I mean, that's double digit growth for a business that a lot of people are in single digits. That's that business has been going double digits right now for for a couple of years now, several quarters. And it's been growing for a combination of great execution from the team and a very very rich pipeline and really across all of these cardiovascular diabetes neurom modulation businesses. So we're very well positioned there. Our electrphysiology business accelerated. Our structural heart business was double digit. Our heart failure business that sometimes gets overshadowed uh grew 14%. Libre which I know very well that you know very well grew 20%. So uh the fundamentals are still there. uh our pharmaceutical business like I also said grew at high single digits 8% so the fundamentals are there Jim and you uh unlike almost every other pharma company I know actually have products that RFK Jr. who's been critical of a lot of the industry seems to believe are life-saving and are done in an appropriate fashion. So yeah, our pharmaceutical business is uh branded generic pharmaceuticals uh in emerging markets. Uh so we bring a very large portfolio to these markets that have great uh fundamentals uh uh growing middle class, aging population, higher birth rates and they're looking for companies like Abbott to bring highquality healthcare uh innovations to the market. So uh so we do very well there also and uh and the and I think your comment that you made about uh Libre and about the health secretary uh yeah we believe that Libre is a great tool to improve behavior improve prevention uh so we're aligned with that also one last question I know that you have always as always one of the greatest balance sheets uh in the SB500 I know that you have a buyback I know you sound like you have conviction that this problem will come to an end can the buyback be used to demonstrate rate uh or to soop up stock that perhaps shouldn't be sold by people who have lost faith when maybe that's a mistake. Well, we have faith in what we're doing, Jim. Like I said to you, we have faith in the fundamentals. Uh we were public about the board authorizing a $7 billion buyback last year. We've got a balance sheet. Uh and we think that this is an overreaction. So, I think I'll just leave it like that. Well, I'll leave it like this. You came on in a not great time. the the executives who duck me on a day like today are executives who I lose faith in. Uh the ones who come on a day like today are the ones I keep faith in and that is Robert Ford Abbott Laboratory's chairman and CEO. Robert, I really appreciate you coming on a tough day. Thank you, Jim. Dad Money's back for coming up. It might be summer, but Kramer is turning in some homework on two names you called in about. He's revealing which ones make the grade next. On Monday, I got stumped by Nicole in California who called in and asked me about a company called Newex Health. Tiny business, never heard of it. This is mainly a healthcare provider. They own and operate 24 mini hospitals and hospital outpatient departments across 11 states with 10 more facilities in various stages of development. Newex also has a much smaller population health management division which owns and operates healthcare provider networks like physicians groups and their affiliates. Basically though, this is a company that runs a network of standalone emergency room facilities. A management says they can treat over 95% of problems that a normal ER can solve with a fraction of the wait time. We're talking about 15 to 30 minutes instead of multiple hours. Filling a crucial gap in our health care system. I like that. The reason that I didn't recognize this one is that Newex Health, as it stands now, was only created three years ago when the old privately held Newex merged with the health management company called Clinigence Holdings in order to come public. On the day the deal was completed, uh, Newex began trading on NASDAQ, its shares skyrocketed a comical 525% to a split adjusted price of $6,000. low came right back down in a matter of weeks. Then it kept going lower because 2022 was a bad time for companies uh to come public through the back door. In fact, as of last summer, New Texas market capitalization dropped as low as $22 million. And the company was almost delisted. It only managed to stay on the NASDAQ uh by executing not one but two reverse splits. Two last year, a one for 15 reverse split in April and then a 1 for 10 reverse split in July. But after stabbing off D-listing, the stocks had an incredible run. In a little over 12 months, DEX rallied from four bucks and change to just under 111 as of as of today. Another staggering move from this thing. Although in the past two months, the stock has come down more than 70 points from its highs. Right now, this thing has a market capitalization of $615 million, which is one big reason why it is so darn volatile. So, what explains that stunning rally from the last year's lows? Okay, in the second half of last year, Newex found a new way to grow its revenue by hiring a third party vendor to assist with bill collection. Hospitals have a huge problem with unpaid bills, and these guys are taking advantage of a relatively new arbitration process to collect. So far, it's been very, very effective. Now, the stock really exploded higher after New Tech reported fourth quarter results at the end of March. The numbers were insanely strong with revenue up 270% year-over-year. Get this, the company earned $112. What do you think Wall Street was expecting? How about a 21cent loss? Again, 90% of their revenue growth was about effectively collecting unpaid medical bills. Armed with this new arbitration tool, Newex was suddenly making much, much more money than anyone imagined they could. And that's why throughout uh the month of April and in early May, as the rest of the market was in rough shape, this stock was flying, climbing from $47 the end of March to that high of $184 and change at the end of May. Actually, sorry, that was miday. Now, these May highs came after New Tech last reported on May 13th when they once again delivered almost comically higher than expected numbers, nearly 212 million in revenue. The analysts were only looking for 134 million, $256 cents per share. What were the analysts looking for? How about $1.77? Same story here again. Management said the new arbitration process accounted for 73% of the year-over-year revenue increase. Now, there are some other factors in play. The company opened new four new micro hospitals last year and that helps adds growth for sure, but it's peanuts compared to better bill collection. So why is the stock coming in over the past couple of months? Well, after a modest pullback in late May, New Tech started pulling back hard in the first week of June, ultimately falling more than 27% that week. Towards the end of that week, an analyst at Benchmark wrote a note explaining that the pullback was because of Blue Cross Blue Shield of Georgia filing a lawsuit against two physician provider groups that are using that same arbitration process that New Texas has had so much success with. Now, look, the lawsuit does involve New Tech, okay? But it's possible the arbitration gravy train all aboard might be facing some additional scrutiny. And that's why I'm reluctant to stick my neck out for this one. I have zero read on the lawsuit Georgia, but the fact that New Tech success in this arbitration process has come so easily out of nowhere makes me worry that perhaps it could go just as easily away out of nowhere. Plus, they've already had two great quarters fueled by the process. In two more quarters, they'll be lapping the changes and those tremendous growth numbers will indeed evaporate. At best, it's a major one-time change that instantly made Newex a lot more profitable. But given that the stocks already have, you know, just up gigantically, you might need a new catalyst if you want more upside. On top of that, hey, how about some yellow flags here? Uh, in late March, Newex delayed the release of its fourth quarter results by a couple days. That's kind of weird. Then in late May, New disclosed that it hired a new order. Not weird, just bad. Neither of these things is dealreaker by itself, but by Let's say they raise eyebrows. Okay, that's what you say when you're afraid to say anything more. Uh, second, early this week, New Tech announced in an AK5 that its COO is leaving. Again, nothing darling here. He's leaving to become the CEO of another company. God love you, but it's not something you want to see. Third, and finally, the whole healthcare provider universe is about to get slammed thanks to the president's big, beautiful budget bill because in a couple of years, there will be major Medicaid cuts and that means less business for hospital operators. In the end, Newex has an interesting story, but it sure feels like I missed it. How about that? Now, because we missed it, it's risky. Hey, next up in LA last night, boy, are we ever up to date. Greg in Michigan asked me about a company called Flex LNG, which has special ships that transport natural gas overseas. And I punt it. Why? Because I was worried that it had a 3.4% dividend yield. And that seems big. When you see such a high yield, it warrants further investigation because often a yeah, I've got everything tonight. A red flag. That's a sign that the investors don't trust the dividend. But after looking at the story, you know what? Get this. I'm actually feeling pretty good about Flex LNG. Looking at the numbers, the dividend feels safe to me, even if the company's balance sheet is is far from clean. Still, FlexNG's dividend has remained constant at 75 cents per uh quarter since mid 2021. Company hasn't had to cut it. In fact, in 2022 and 2023, they threw in some additional special dividends. I don't expect that again, but I'm not worried about the normal payout. They consistently generate much more free cash flow than they need to pay the dividend. This year the projected cash flow is a bit lower than the de total dividend but company has 4 million in cash as of the latest quarter and it has no major debt repayments before 2028 2028. So I think they'll be fine but I think the fact that it doesn't have the money to cover right now is making people nervous. More important Flex LG operates in an increasingly strong business. Almost all their natural gas transportation fleet is contracted out for several years into the future. So you know what? You've got my blessing. You can buy this one for the 13% yield, even if I don't necessarily expect a higher share price given the profits have been steadily falling, not rising. Here's the bottom line. Newex Health uh feels just too risky for me. Sorry. Don't buy. Don't buy. But if you're looking for a big dividend, you can do a lot worse than Flex Lng. I feel like calls. I want to speak to Chris in Pennsylvania. Chris. Yes. Uh Jim, uh nice to talk to you. I would like to know the status of Novo Nordisk. Uh it has gone up to $140. I want you to know I don't want Nova notice because I ex name Novo. And the reason that is because like you if there's going to be talk about about uh tariffs on foreign drugs versus Eli Liy, Novo is going to have an even less of an edge less of an edge on this thing. So I say Novo, we don't need the bottom fish. It's not for me. I want to go to Mike in Florida. Mike, booyah, Mr. Kramer, how are you? Booyah. I am just super. Mike, everything everything broke my way today. I don't know about you. I love it. I'm right there with you. Uh, I'm calling from beautiful sunny South Florida. Stewart, Florida to be exact. I like Stewart, Florida. Oh, I love it. It's beautiful here. Great golf. If I like FO, too. If you want to get into it, I like FO. My wife likes Del I maybe we we'll get to Florida but take it offline. What do we got for Stockwise? So I'm a big time nuclear advocate. Those that know me well know me as the uh nuclear average Joe and I love your show first and foremost. Oh, thank you. People think I radiate. Yeah, it's all right. I listen. So the stock that I have a question on today is Centress Energy, thicker L EU. Okay. And I know the company Centrist Energy fits in this in this particular niche that I've been saying along with Alo. I am not going to go against anybody who wants to buy uranium or nuclear cuz it's coming back. Do I think it's going to come back within the time frame of the stocks that no longer necessary. We have a new kind of market. I believe as you can be when you get the book that comes out at the end of of September, how to make money in any market, you will see that I endorse having one speculative position in your portfolio. Make centress your speculative position and I say you are on my team. You will make money in any market. All right. Uex held is an interesting play but it's a bit risky right now. Hey, but this flex LG you could do a lot worse after big dividend. Much more made money. Gold and copper prices have hit record highs this year. Are we doing the right thing to bring enough gold into this country since it's so important for us? Why don't we check with the man who introduced me to the concept of how much gold comes from making copper with Dr. Mark Bristo Barrack Mining and then a short-term peak may be forming for the top GOP-1 player just telling us that is that's why I had to tell that questioner look out and of course all your calls rapid fire in tonight's edition of the lightning round so stay with Kramer when it comes to precious metals doesn't get much better than gold up roughly 27 7% this year. But in terms of markets now in general, do you know that copper is now ahead? That's up 37% for the year. Partly thanks to demand for all these data centers that are being built and partly because President Trump just announced a 50% tariff on imported copper effective August 1. Which brings me to Barrack Mining, the old Barrack Gold, which is mainly in the gold business, but also some copper mines in Chile and Zambia, Saudi Arabia, as well as some new projects in development because they've been pretty aggressive about expanding into copper. As Matter of fact, I learned about copper from the man we're about to speak to. Given how much these two metals have run, where do we go from here? Let's check in with Dr. Mark Bristo. He's the president CEO of Barrack Mining Corporation to find out. Mark, welcome back to Man Money. Jim, how you doing? I am doing fine, thanks. And I always want to thank you for your toutelage. I know that you once told me, Jim, you're you're chronically underestimating how much gold is, how much copper is produced as a byproduct of gold mining, and one day that might matter. I think, sir, that day has come and I want to know what you're doing about it. Well, you know, couldn't be in two better metals. Uh the gold price is up and and again we we're seeing a a squeeze on the supply side and a and a and and a growing demand and and copper is even better positioned. And why? Because miners haven't invested in their future and we've just really unlocked the resources in our oil bodies with a rising gold price rather than investing in the future. And to your point you just made, copper is in this exactly the same boat. And as you know, I'm a big investor in mining. I believe in long-term investment and it ultimately pays off. Now Mark, we have a president of the United States who obviously completely agrees with you. And he also uh is not happy with the fact that so many copper smelters have been closed by environmentalist. These are his words. And he feels like that it's possible that you could we could change pretty much everything and get it. So is once again efficient. If we did change the environmental laws in this country and we have better technology now than when we did it when we established the the laws, would you be able to mine even more copper just as a standalone business and make good money? I mean of course uh and that is one of the biggest challenges is look the technology for copper smelters just on on on copper um is advanced so much that we get um the top copper smelters in the world now can extract all the other metals that come with copper and so the cost of smelting copper uh through a smelter is almost zero. Wow. In fact, recently we've been paid to ship con concentrate to the smelters. Wow. Well, I wonder uh this is an administration that has a unique relationship with business and the people that are watching the show who don't like business and don't like gold and don't like are worried about the environment. Don't listen to this. You don't have to listen to me. But they want to talk to you. The uh the energy secretary wants to talk to you. The president is interested in this. Is it possible because you are the dean of the group to get something going that would make it so that people could understand in Washington that copper is no longer as dirty and that we have to make sure that the Chinese don't own this market because this is about the data center. This is about electronic vehicles and it's about the future of the country not being held hostage to China. Yes. and and um Jim I mean look the the big challenge is people don't appreciate that we need metals to survive first of all in the developed world and in United States particularly if you ask the average folk how much copper or any metal does the United States consume no one will know but it consumes as much as the rest of the developed world and um it needs that metal not only to grow which is growing all the time but to reindustrialize and and to your point that for us to have a planet that our children's childrens can live in we need to continue to reindustrialize and you and I have discussed this before also for us to really have a world for the whole of humanity to survive survive and prosper in. We need to uplift those countries and populations that have been left behind by society. So to do that and and you know there's a there's there's some great statistics. If we if we didn't have mining, we wouldn't be able to grow all the food that just the people today on Earth need to survive because we wouldn't have tractors, we wouldn't have plows. And if we if we didn't have mining, we wouldn't have big cities. So the footprints of our cities would be a lot bigger. And so, you know, and then get to copper. Copper is is a unique metal. I always say gold is precious and copper is as strategic as gold is precious because it doesn't have any substitutes and it's needed uh for a futurefacing world. Do we have a lot of copper in the United States? Yes, of course we do. We have enough to be able to meet our needs. The United States has enormous mineral endowments. Not only, as you know, we the biggest gold miners in the world and and our biggest mining complexes in the United States. Um, we mine a small amount of copper in in the United States, but there's certainly significant endowment uh across the Midwest of the United States. And the reason why we're not mining it is because uh the smelters have been treat been turn shut down over and over again because of environmental laws. So let me explain to you. It takes about 20 to 40 years to develop a mine in the United States. We're building a mine in Pakistan, one of the biggest gold copper mines in the world. And we started construction this year. we will be producing in 2028. There you go. Just to put it in perspective. All right. Well, I'm going to leave it there, but as always, first I want to thank you. For years, I I I totally ignored copper. You told me to stop ignoring it. Now, I feel like I should stop I should start ignoring gold because copper is the coin of the realm if we're going to continue to be technologically superior. No, I think gold is Make sure that you keep a focus on gold. Uh Jim, it's uh it's still got a long way to go. Of course it does. I agree with you. You know that. That's Dr. Mark Bristo. He's the president CEO of Barrack Mining Corp. I'm Mark. I knew you'd come on and explain it as as cogently as possible. Next time we'll talk about Mali and the tougher places. This time was devoted to what you can do for your country, which is for our country, which says to me that you can make this copper deficit go away if you get the opportunity. Thank you. Yeah. Money's back. Coming up, Kramer takes your calls and the sky's the limit. It's a fast fire lightning round. Next, it is time. It's time for the light for no stock by step play and then the lightning round is over. Are you ready Steve D with Dan in South Carolina Dan? How you doing? Dan from South Carolina. I got a question. How you doing Kramer? Sure. I'm doing all right. How are you partner? Good. Good. COP, I've been wondering. All right. Why COP? Let me tell you, I just told Jeff Marx, my partner uh for the club, that we're in the wrong one now. Cotara is not delivering. We should be in Kico Phillips. I just said it today. I'm not going to say it behind my back. I tell it to you, I say it to him. That's how I play it. Let's go to Aaron in Texas. Aaron, booyah, Jim, nice, nice to meet you. Uh, true. I like that. What's going on? Nice. Let me let me ask you about AMD. Do you think Lisa Sue can get it to a trillion dollar market cap? I don't know, but it's going in the right direction. I mean, they obviously have now good GPUs. There's GPU shortage everywhere. Stocks had a real big run off the bottom. I do think you could have a pullback, but I do think that she's got what it takes to be able to take that stock much higher. How about we go to Jim in Florida, Jim? Jimmy Chill, a bit hot, a big hot and steamy Naples, Florida booya to you. Okay, I'll take that. What's happening? My question is on a tech company that is going through some restructuring and some management changes and has a market cap of 2.2 billion, debt of 1.9 billion, uh, but it appears as if their free cash flow is increasing quite rapidly. currently pays a 2.38% dividend with a new uh CEO Kurt Wolf uh as of May 20 25. Would you buy, sell or hold PBI? You know, I got to look at PBI again. I got I got snookered on PBI there. There was a turnaround that they told me was going to work and it didn't work and I kind of walked away from it. Let me let me open the book again on it because it's a story company that I really liked. Okay, I promise I will do that. I need to go and I apologize in advance to Ilhham in Virginia. oil. Hey Jim, how are you? I'm doing good. How are you? Good, good. I am a club member and longtime listener. Thanks to you and to your team for the valuable advice. Uh calling from Tyson Corner, Virginia. Okay. I'm wondering on uranium stock CCJ. I like CCG. It's one of the stocks. It's one of those along with Alo and the small form reactors too. I just think that this is a winner. What am I going to say? I am pro- nuke and I think people should be in them. And that, ladies and gentlemen, is conclusion of the lightning round. The lightning round is sponsored by Charles Schwab. Coming up, are cracks developing in the GLP-1 thesis. Kramer is digging into the earnings numbers that'll have Wall Street weighing their options on the drug stocks. Next. Booyah Jim. Your integrity makes you the booyah saint of Wall Street. Booyah. Jimmy Chill. Booyah. Jimmy Chill. Booyah. Jim. Quadruple. That's a lot of booya. For years. We've all presumed that these GOP-1 weight loss wonder drugs would change the world. The promise of instant weight loss was so compelling that we expected wholesale changes in behavior. The street went nuts with it, drawing wildly absurd conclusions about what would happen, not just in food and restaurant stocks. For example, when the fear of GOP-1s first swept the industry in September of 2023, the brokerage house Jeff put out a piece arguing that the huge global market for these drugs by 2030 would mean great news for the airlines. The research research note titled quote way to go airlines implications of a slimmer society end quote actually posited that GOP-1s could mean the average flyer loses 10 lb which translates into a weight loss of 1,790 lbs per flight and means massive fuel savings for the airlines. So you should go buy the airlines stocks. Now I I said at the time that that was the peak of the research hysteria and it to make you wonder about the hype around the GOP-1 drugs. Today we got our first data point that makes me wonder if the GOP Josh ones themselves may have hit a short-term peak. I'm talking about the dramatically better than expected quarter from PepsiCo. It was a Twitter force on all accounts, especially international. When you read through the conference call and you speak to CEO Ramlu, it's hard not to question whether something negative has happened in the world of the GOP-1 drugs because the free delay numbers which have been weak, a weakness presumed to be in part caused by GOP-1 use have suddenly turned up. Now maybe PepsiCo has figured out how to make portion sizes that can still entice people who are taking a Zmpic or Monaro. That's the trick because these drugs make you feel like you're full on less food. So perhaps a smaller size bag is just a winner. Or maybe PepsiCo has come up with new flavors that can literally beat the GLP-1s because these drugs reduce your cravings for all sorts of stuff. But who knows if there really is a chemical workaround for Doritos and definitely possible. However, what I'm thinking as someone who owns Eli Lloyd for the Chapel Trust and who wishes I own PepsiCo is that there might be a short-term peak in the use of these drugs. The Achilles heel of these drugs is that they're too effective. At some point, you lose enough weight and you might think you can stop taking them. So far, it looks like that might be happening with people who've been on these things for a year. Maybe they just don't understand that the weight comes right back on when you stop taking them. We know there are numbers that show a big drop off in GOP1-1 use after a little more than a year. Maybe people have had it with giving themselves needles. Or maybe there just aren't enough people willing to pay full price until a few months ago compoundingies could still sell cheaper generic versions because there was a serious shortage. That's now over. In the end, I think it's probably hard to keep taking this stuff once you're thin. Whatever the case, if Eli Liy is going to break out from this level, it needs breakthroughs in new areas. heart brain that it just doesn't have right now. Or there has to be some new data that shows something else positive that the GOP1 drugs can do. And of course, it's got to start coming in pill form because people are tired of taking needles. I still like the stock of Eli Liy. We have a huge gain this one for the travel trust. We're going to hang on to it for now. But PepsiCo's breakout, a lack of Lily's breakthroughs, and a reminder that at one point we were thinking of buying the airlines because of these GOP-1 drugs means that I no longer feel as certain about Lily's future without science that says these drugs do a lot more than just control diabetes and make you lose some weight. Alex says always bull market somewhere. I promise I find it just for you right here on Mad Money. I'm Jim Kramer. See you next time. All opinions expressed by Jim Kramer on this podcast are solely Kramer's opinions and do not reflect the opinions of CNBC, NBC Universal, or their parent company or affiliates and may have been previously disseminated by Kramer on television, radio, internet, or another medium. You should not treat any opinion expressed by Jim Kramer as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Kramer's opinions are based upon information he considers reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. To view the full MadMoney disclaimer, please visit cnbc.com/madmoney disclaimer.